New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
09:37 EDTGSK, AMGNAmgen to pay GlaxoSmithKline $275M to terminate denosumab collaboration pact
Amgen (AMGN) disclosed in a regulatory filing that the company and Glaxo Group (GSK) entered into an agreement terminating in part and amending in part the collaboration agreement dated as of July 27, 2009 relating to the commercialization of denosumab for osteoporosis indications in certain geographic territories. The transition agreement terminates the prior collaboration agreement for all countries and regions of the collaboration territory, including the European Union, Switzerland, Norway, Russia and Mexico, except for Australia. All commercial activities assigned to GSK under the collaboration agreement other than those in Australia will be transitioned back to Amgen no later than December 31. In exchange for the early termination, except Australia, Amgen will pay to GSK an initial payment and specific milestones over the transition period totaling $275M. In addition, Amgen will reimburse GSK $15M for costs incurred by GSK in performing its obligations. The transition agreement does not change the terms of the separate expansion agreement dated as of July 27, 2009 relating to the commercialization of denosumab for all indications in certain geographic territories, Amgen said.
News For AMGN;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 19, 2014
07:09 EDTAMGNJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 18, 2014
16:02 EDTAMGNAmgen presents long-term data on safety, efficacy of evolocumab
Subscribe for More Information
09:23 EDTAMGNAmgen to host conference call
Management discusses Amgen's cardiovascular program, as well as the evolocumab data presented at the American Heart Association (AHA) Scientific Sessions 2014, on a conference call to be held on November 18 at 7 pm. Webcast Link
07:20 EDTGSKEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information
07:03 EDTAMGNAmgen management to meet with UBS
Meeting to be held in Zurich on November 18 hosted by UBS.
November 17, 2014
17:02 EDTGSKClovis in oncology clinical trial collaboration with GlaxoSmithKline
Subscribe for More Information
05:32 EDTGSKMedidata announces collaboration with GlaxoSmithKline
Medidata (MDSO) announced the completion of a method development project conducted in partnership with GlaxoSmithKline (GSK) to evaluate the impact of unifying mobile health, or mHealth, devices with cloud-based technologies in a clinical trial setting. The joint initiative assessed the capabilities of mHealth tools and evaluated how they could be used to enable a new model for clinical trial conduct that aligns site and patient needs with faster study execution and reduced costs. The collaborative project, which took place at GSK’s Human Performance Lab, demonstrated that mHealth technologies have the power to comprehensively collect large volumes of objective data that is reliable, secure and analysis-ready, and provides real-time, continuous insight into the well being of patients. All of the data collected was audited and is compliant with FDA regulations. Additionally, the effort indicated that mobile devices can support the long-term goal of lessening the burden on patients participating in studies by streamlining routine procedures, eliminating unnecessary ones and reducing visits to clinical trial sites.
November 14, 2014
16:58 EDTAMGNThird Point gives quarterly update on stakes
NEW STAKES: Alibaba (BABA), eBay (EBAY), Bed Bath & Beyond (BBBY), Shire (SHPG), and Parker Hannifin (PH). INCREASED STAKES: Actavis (ACT), Amgen (AMGN), EQT (EQT), Sensata (ST), Coca-Cola Enterprises (CCE). DECREASED STAKES: Williams Cos (WMB), Ally Financial (ALLY), Cheniere Energy (LNG), YPF (YPF), and FedEx (FDX). LIQUIDATED STAKES: AIG (AIG), T-Mobile (TMUS), Rackspace (RAX), Hertz (HTZ), and Citrix Systems (CTXS).
14:53 EDTGSKCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
09:38 EDTAMGNJANA Partners gives quarterly update on stakes
NEW STAKES: AMD (AMD), AECOM Technology (ACM), Alibaba (BABA), McDonald's (MCD), Amgen (AMGN), Gaming and Leisure Properties (GLPI), Iron Mountain (IRM), iRobot (IRBT), Seadrill Partners (SDLP), Valeant (VRX). INCREASED STAKES: eBay (EBAY), Charter (CHTR), Groupon (GRPN), HD Supply (HDS), Hertz (HTZ). DECREASED STAKES: Apache (APA). LIQUIDATED STAKES: CBS (CBS), Endo (ENDP), FMC Corporation (FMC), SeaWorld (SEAS), SunEdison (SUNE).
09:37 EDTAMGNJANA reports new stakes in McDonald's, AECOM, Amgen
Subscribe for More Information
07:14 EDTAMGN, GSKAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
12:59 EDTGSKApollo plans bid for GSK mature drugs business, Reuters reports
Subscribe for More Information
November 12, 2014
09:16 EDTGSKLigand reports GlaxoSmithKline EU regulatory submission for Revolade
Subscribe for More Information
08:53 EDTGSKGlaxoSmithKline weakness creates buying opportunity, says Argus
After GlaxoSmithKline cut its near-term EPS guidance, Argus still believes that the company's deals with Novartis (NVS) should boost its EPS growth in the years ahead, likely as soon as 2015. The firm thinks the stock is a good value for long-term investors, and it keeps a Buy rating on the shares.
08:18 EDTGSKUBS to hold a conference
Subscribe for More Information
November 11, 2014
16:05 EDTAMGNAmgen, AstraZeneca say Phase 3 brodalumab study met endpoints
Subscribe for More Information
10:44 EDTAMGNAmgen reaffirms 2015 adjusted EPS outlook $9.05-$9.40
Subscribe for More Information
November 10, 2014
16:07 EDTGSKUBS to hold a conference
UBS European Conference is being held in London, England on November 11-12.
15:54 EDTAMGNAmerican Society of Nephrology to hold a conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use